Description
Background:
Lebrikizumab is a humanized monoclonal antibody and an experimental immunosuppressive drug for the
treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. Lebrikizumab blocks
interleukin 13 (IL-13), a cytokine (cell-signalling protein) that is produced by a type of white blood cell called Th2
cells.
Intended Use:
For Estimation of Lebrikizumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!